

Table L3
Child^a Lifetime Asthma^b Prevalence
and Weighted Number^c by Age and State or Territory: BRFSS 2021

State	Age Group	Sample Size ^d	Prevalence (Percent)	Standard Error	95% CI ^e (Percent)	 	Weighted Number ^c	95% CI ^e Weighted Number ^c
Total ^f	0–4	10,645	4.9	0.52	(4.0–6.0)		644,308	(505,416–783,199)
Total ^f	5–9	12,141	9.3	0.54	(8.3–10.4)		1,240,125	(1,095,549–1,384,701)
Total ^f	10–14	18,260	12.6	0.66	(11.4–14.0)		1,692,185	(1,513,081–1,871,290)
Total ^f	15–17	12,038	16.0	0.85	(14.4–17.7)		1,353,996	(1,200,644–1,507,348)
AL	0–4	169	6.7	2.18	(3.5–12.5)		19,363	(6,983–31,743)
AL	5–9	217	13.8	3.09	(8.8–21.0)		40,351	(21,525–59,178)
AL	10–14	298	16.1	3.30	(10.7–23.7)		46,508	(25,705–67,311)
AL	15–17	206	20.7	3.45	(14.8–28.3)		38,727	(24,906–52,548)
CA	0–4	380	6.0	1.72	(3.4–10.3)		137,366	(57,167–217,564)
CA	5–9	416	5.6	1.18	(3.7–8.4)		130,317	(76,191–184,443)
CA	10–14	357	10.6	2.31	(6.9–16.1)		263,403	(148,169–378,637)
CA	15–17	282	14.2	2.78	(9.6–20.6)		218,359	(128,088–308,630)
CT	0–4	310	10.3	2.99	(5.8–17.8)		18,406	(7,240–29,572)
CT	5–9	410	9.0	2.02	(5.8–13.9)		16,771	(9,215–24,327)
CT	10–14	646	16.7	2.28	(12.7–21.7)		32,360	(22,975–41,744)
CT	15–17	394	19.0	3.37	(13.2–26.4)		24,988	(15,119–34,857)
DC	0–4	180	11.7	3.73	(6.1–21.2)		4,666	(1,523–7,809)
DC	5–9	116	14.1	4.17	(7.7–24.4)		5,603	(2,205–9,002)
DC	10–14	104	20.7	5.12	(12.4–32.5)		5,136	(2,399–7,874)
DC	15–17	79	21.6	5.75	(12.4–34.9)		4,906	(2,088–7,723)
GA	0–4	252	7.4	3.24	(3.1–16.8)		45,707	(4,199–87,215)
GA	5–9	297	12.7	3.13	(7.7–20.2)		83,035	(39,736–126,335)
GA	10–14	448	17.0	2.67	(12.4–22.9)		110,861	(73,854–147,869)
GA	15–17	325	23.1	3.90	(16.4–31.6)		97,035	(60,118–133,952)
HI	0–4	301	4.0	1.81	(1.6–9.5)		3,457	(345–6,569)
HI	5–9	336	6.7	2.59	(3.1–13.9)		5,859	(1,273–10,446)

For additional information on methods and variable description, refer to “Technical Information,” available at: <https://www.cdc.gov/asthma/brfss/2021/child/brfsschildtechinfo.html>

^aAged 0–17 years

^bLifetime question: Has a doctor, nurse or other health professional ever said that the child has asthma?

^cWeighted number of respondents who answered the lifetime asthma question

^dUnweighted number of respondents who answered the lifetime asthma question

^eCI denotes confidence interval

^fTotal includes data from 29 states and DC but excludes Puerto Rico and U.S. Virgin Islands

(–) or empty cell: Suppressed if the normal approximation to the binomial distribution does not apply due to small sample size or relative standard error (RSE) > 30%

Table L3
Child^a Lifetime Asthma^b Prevalence
and Weighted Number^c by Age and State or Territory: BRFSS 2021

State	Age Group	Sample Size ^d	Prevalence (Percent)	Standard Error	95% CI ^e (Percent)	 	Weighted Number ^c	95% CI ^e Weighted Number ^c
HI	10–14	620	12.4	2.35	(8.5–17.8)		10,121	(6,185–14,057)
HI	15–17	296	10.8	2.83	(6.4–17.7)		5,215	(2,513–7,916)
IL	0–4	84			(.–)		39,386	(.–)
IL	5–9	107	7.2	2.78	(3.3–15.0)		53,731	(12,851–94,612)
IL	10–14	211	10.6	2.41	(6.7–16.3)		70,982	(38,408–103,555)
IL	15–17	98	16.6	4.87	(9.0–28.4)		61,072	(23,486–98,658)
IN	0–4	411	7.0	1.49	(4.6–10.5)		28,191	(16,041–40,342)
IN	5–9	387	8.8	1.81	(5.8–13.1)		36,222	(20,914–51,530)
IN	10–14	742	11.8	1.65	(8.9–15.4)		47,871	(34,081–61,662)
IN	15–17	408	15.2	2.21	(11.4–20.1)		40,392	(28,479–52,305)
KS	0–4	834	3.1	0.64	(2.0–4.6)		5,616	(3,285–7,946)
KS	5–9	1,021	9.1	1.11	(7.1–11.5)		16,805	(12,662–20,947)
KS	10–14	1,463	14.2	1.27	(11.9–16.9)		26,037	(21,285–30,789)
KS	15–17	854	17.9	1.76	(14.7–21.6)		21,202	(16,789–25,614)
KY	0–4	187			(.–)		6,319	(.–)
KY	5–9	240	7.6	1.97	(4.5–12.5)		19,308	(9,428–29,187)
KY	10–14	333	9.9	2.09	(6.5–14.8)		24,294	(14,077–34,511)
KY	15–17	228	16.2	3.34	(10.6–23.8)		26,021	(14,820–37,222)
ME	0–4	344			(.–)		660	(.–)
ME	5–9	400	11.3	2.24	(7.6–16.5)		6,912	(4,074–9,750)
ME	10–14	571	16.2	2.72	(11.5–22.2)		9,911	(6,332–13,491)
ME	15–17	407	15.5	2.54	(11.1–21.1)		6,356	(4,220–8,491)
MD	0–4	582	3.1	0.92	(1.7–5.5)		11,089	(4,520–17,657)
MD	5–9	637	11.1	1.83	(8.0–15.2)		40,612	(26,890–54,335)
MD	10–14	1,190	12.5	1.64	(9.6–16.0)		44,536	(32,252–56,820)
MD	15–17	725	19.6	2.38	(15.4–24.7)		43,263	(32,076–54,449)

For additional information on methods and variable description, refer to “Technical Information,” available at: <https://www.cdc.gov/asthma/brfss/2021/child/brfsschildtechinfo.html>

^aAged 0–17 years

^bLifetime question: Has a doctor, nurse or other health professional ever said that the child has asthma?

^cWeighted number of respondents who answered the lifetime asthma question

^dUnweighted number of respondents who answered the lifetime asthma question

^eCI denotes confidence interval

^fTotal includes data from 29 states and DC but excludes Puerto Rico and U.S. Virgin Islands

(.–) or empty cell: Suppressed if the normal approximation to the binomial distribution does not apply due to small sample size or relative standard error (RSE) > 30%

Table L3
Child^a Lifetime Asthma^b Prevalence
and Weighted Number^c by Age and State or Territory: BRFSS 2021

State	Age Group	Sample Size ^d	Prevalence (Percent)	Standard Error	95% CI ^e (Percent)	 	Weighted Number ^c	95% CI ^e Weighted Number ^c
MA	0–4	249	5.4	2.04	(2.6–11.1)		18,056	(4,419–31,693)
MA	5–9	371	14.2	2.90	(9.4–20.9)		45,693	(25,731–65,656)
MA	10–14	428	17.1	2.46	(12.8–22.4)		58,722	(40,727–76,718)
MA	15–17	311	21.9	3.63	(15.6–29.8)		47,759	(30,067–65,451)
MI	0–4	282			(–)		8,672	(–)
MI	5–9	381	12.1	2.17	(8.5–17.1)		66,491	(41,945–91,038)
MI	10–14	522	11.9	2.02	(8.4–16.5)		66,029	(42,974–89,083)
MI	15–17	405	18.7	2.57	(14.2–24.3)		67,827	(47,800–87,854)
MN	0–4	552	1.7	0.87	(0.6–4.6)		5,901	(0–12,015)
MN	5–9	668	9.0	1.59	(6.4–12.7)		32,266	(20,642–43,890)
MN	10–14	1,299	11.0	1.18	(8.9–13.5)		37,452	(29,347–45,556)
MN	15–17	752	15.2	2.11	(11.6–19.9)		33,658	(23,565–43,751)
MS	0–4	260	7.7	2.96	(3.6–15.9)		13,568	(3,104–24,032)
MS	5–9	231	15.3	3.37	(9.8–23.2)		25,458	(13,537–37,379)
MS	10–14	297	16.5	2.78	(11.7–22.7)		31,780	(20,546–43,014)
MS	15–17	175	12.2	2.84	(7.6–18.9)		13,403	(7,132–19,675)
MO	0–4	634	5.5	1.53	(3.2–9.4)		19,871	(8,843–30,899)
MO	5–9	627	9.8	1.81	(6.7–13.9)		33,230	(20,756–45,705)
MO	10–14	729	15.2	2.35	(11.1–20.4)		54,961	(36,984–72,938)
MO	15–17	588	14.6	2.73	(10.0–20.8)		33,158	(19,922–46,394)
MT	0–4	235	4.0	1.33	(2.1–7.6)		2,495	(883–4,106)
MT	5–9	348	5.5	1.27	(3.5–8.6)		3,282	(1,788–4,776)
MT	10–14	412	9.1	1.81	(6.1–13.3)		5,464	(3,259–7,668)
MT	15–17	265	14.9	2.96	(10.0–21.7)		5,460	(3,140–7,781)
NE	0–4	689	1.8	0.63	(0.9–3.6)		2,402	(774–4,029)
NE	5–9	741	7.9	1.74	(5.1–12.1)		10,261	(5,620–14,902)

For additional information on methods and variable description, refer to “Technical Information,” available at: <https://www.cdc.gov/asthma/brfss/2021/child/brfsschildtechinfo.html>

^aAged 0–17 years

^bLifetime question: Has a doctor, nurse or other health professional ever said that the child has asthma?

^cWeighted number of respondents who answered the lifetime asthma question

^dUnweighted number of respondents who answered the lifetime asthma question

^eCI denotes confidence interval

^fTotal includes data from 29 states and DC but excludes Puerto Rico and U.S. Virgin Islands

(–) or empty cell: Suppressed if the normal approximation to the binomial distribution does not apply due to small sample size or relative standard error (RSE) > 30%

Table L3
Child^a Lifetime Asthma^b Prevalence
and Weighted Number^c by Age and State or Territory: BRFSS 2021

State	Age Group	Sample Size ^d	Prevalence (Percent)	Standard Error	95% CI ^e (Percent)	 	Weighted Number ^c	95% CI ^e Weighted Number ^c
NE	10–14	966	9.7	1.48	(7.1–13.0)		12,428	(8,541–16,315)
NE	15–17	774	13.7	1.91	(10.3–17.9)		10,766	(7,712–13,820)
NH	0–4	119			(.–.)		1,768	(.–.)
NH	5–9	149	10.4	2.59	(6.3–16.7)		7,011	(3,557–10,466)
NH	10–14	288	11.8	2.11	(8.3–16.6)		7,814	(5,018–10,610)
NH	15–17	275	21.0	3.66	(14.7–29.0)		9,431	(5,740–13,122)
NJ	0–4	363	3.8	1.36	(1.8–7.5)		18,794	(5,345–32,243)
NJ	5–9	433	7.7	1.64	(5.1–11.6)		37,963	(21,735–54,191)
NJ	10–14	527	11.3	2.04	(7.9–16.0)		59,065	(37,329–80,801)
NJ	15–17	309	12.2	2.53	(8.0–18.1)		41,666	(23,975–59,356)
NM	0–4	271	3.2	1.66	(1.1–8.6)		3,932	(0–7,984)
NM	5–9	320	8.8	1.89	(5.8–13.3)		10,936	(6,291–15,581)
NM	10–14	546	10.2	1.75	(7.3–14.2)		12,672	(8,336–17,008)
NM	15–17	275	15.2	2.88	(10.4–21.8)		12,818	(7,856–17,781)
NY	0–4	520	6.1	1.54	(3.7–9.9)		62,983	(31,461–94,505)
NY	5–9	524	8.1	2.19	(4.7–13.6)		90,052	(41,447–138,657)
NY	10–14	658	10.7	1.77	(7.7–14.7)		120,038	(81,020–159,056)
NY	15–17	470	15.6	3.23	(10.2–23.0)		106,499	(59,213–153,784)
OH	0–4	409	3.8	1.50	(1.7–8.1)		26,200	(5,545–46,856)
OH	5–9	475	7.8	1.50	(5.3–11.3)		53,675	(33,228–74,122)
OH	10–14	888	11.6	1.68	(8.7–15.4)		78,984	(55,493–102,474)
OH	15–17	733	13.2	1.73	(10.2–17.0)		55,774	(41,398–70,150)
PA	0–4	212	3.4	1.49	(1.5–7.9)		24,120	(3,464–44,776)
PA	5–9	263	10.2	2.41	(6.4–16.0)		67,904	(35,321–100,486)
PA	10–14	417	14.6	2.43	(10.4–20.0)		91,696	(60,762–122,630)
PA	15–17	286	17.4	3.87	(11.1–26.3)		73,959	(37,759–110,158)

For additional information on methods and variable description, refer to “Technical Information,” available at: <https://www.cdc.gov/asthma/brfss/2021/child/brfsschildtechinfo.html>

^aAged 0–17 years

^bLifetime question: Has a doctor, nurse or other health professional ever said that the child has asthma?

^cWeighted number of respondents who answered the lifetime asthma question

^dUnweighted number of respondents who answered the lifetime asthma question

^eCI denotes confidence interval

^fTotal includes data from 29 states and DC but excludes Puerto Rico and U.S. Virgin Islands

(.–.) or empty cell: Suppressed if the normal approximation to the binomial distribution does not apply due to small sample size or relative standard error (RSE) > 30%

Table L3
Child^a Lifetime Asthma^b Prevalence
and Weighted Number^c by Age and State or Territory: BRFSS 2021

State	Age Group	Sample Size ^d	Prevalence (Percent)	Standard Error	95% CI ^e (Percent)	 	Weighted Number ^c	95% CI ^e Weighted Number ^c
RI	0–4	195	3.7	1.58	(1.6–8.4)		2,045	(287–3,803)
RI	5–9	229	10.1	2.77	(5.8–16.9)		5,649	(2,438–8,861)
RI	10–14	482	12.8	2.20	(9.0–17.7)		7,073	(4,536–9,610)
RI	15–17	256	15.1	2.57	(10.7–20.9)		5,438	(3,621–7,254)
TX	0–4	499	5.5	1.47	(3.2–9.2)		103,344	(47,670–159,017)
TX	5–9	515	11.0	2.03	(7.6–15.7)		221,390	(138,836–303,945)
TX	10–14	787	13.5	2.41	(9.5–19.0)		263,091	(165,754–360,427)
TX	15–17	458	16.4	3.04	(11.3–23.2)		206,836	(125,337–288,334)
UT	0–4	648	1.7	0.58	(0.9–3.3)		4,348	(1,441–7,256)
UT	5–9	646	7.7	1.29	(5.5–10.7)		20,024	(13,289–26,759)
UT	10–14	1,197	13.4	1.41	(10.9–16.4)		34,025	(26,522–41,529)
UT	15–17	771	12.1	1.39	(9.6–15.1)		18,324	(14,063–22,586)
VT	0–4	214	3.3	1.30	(1.5–7.1)		970	(223–1,717)
VT	5–9	330	10.2	2.66	(6.0–16.7)		3,072	(1,407–4,737)
VT	10–14	426	10.4	1.89	(7.3–14.7)		3,311	(2,096–4,525)
VT	15–17	331	11.3	1.97	(7.9–15.8)		2,387	(1,611–3,162)
WI	0–4	211			(–.)		4,614	(–.)
WI	5–9	215	14.6	4.28	(8.0–25.1)		49,065	(17,973–80,156)
WI	10–14	348	15.4	3.84	(9.3–24.5)		54,319	(24,497–84,142)
WI	15–17	261	9.4	1.95	(6.2–14.0)		20,424	(12,633–28,215)
Territory								
PR	0–4	186	9.8	2.63	(5.8–16.3)		16,890	(7,571–26,209)
PR	5–9	242	19.9	3.06	(14.6–26.6)		36,156	(24,021–48,292)
PR	10–14	276	20.9	2.81	(15.9–26.9)		40,278	(28,803–51,753)
PR	15–17	186	21.6	3.65	(15.2–29.6)		28,110	(18,396–37,825)
VI	0–4	49			(–.)		0	(–.)

For additional information on methods and variable description, refer to “Technical Information,” available at: <https://www.cdc.gov/asthma/brfss/2021/child/brfsschildtechinfo.html>

^aAged 0–17 years

^bLifetime question: Has a doctor, nurse or other health professional ever said that the child has asthma?

^cWeighted number of respondents who answered the lifetime asthma question

^dUnweighted number of respondents who answered the lifetime asthma question

^eCI denotes confidence interval

^fTotal includes data from 29 states and DC but excludes Puerto Rico and U.S. Virgin Islands

(–.) or empty cell: Suppressed if the normal approximation to the binomial distribution does not apply due to small sample size or relative standard error (RSE) > 30%

Table L3
Child^a Lifetime Asthma^b Prevalence
and Weighted Number^c by Age and State or Territory: BRFSS 2021

State	Age Group	Sample Size ^d	Prevalence (Percent)	Standard Error	95% CI ^e (Percent)	 	Weighted Number ^c	95% CI ^e Weighted Number ^c
VI	5–9	91	17.9	7.62	(7.3–37.6)		1,174	(79–2,269)
VI	10–14	60	16.6	8.38	(5.7–39.5)		1,243	(0–2,609)
VI	15–17	41	17.9	11.28	(4.6–49.6)		875	(0–2,061)

For additional information on methods and variable description, refer to “Technical Information,” available at:
<https://www.cdc.gov/asthma/brfss/2021/child/brfsschildtechinfo.html>

^aAged 0–17 years

^bLifetime question: Has a doctor, nurse or other health professional ever said that the child has asthma?

^cWeighted number of respondents who answered the lifetime asthma question

^dUnweighted number of respondents who answered the lifetime asthma question

^eCI denotes confidence interval

^fTotal includes data from 29 states and DC but excludes Puerto Rico and U.S. Virgin Islands

(–) or empty cell: Suppressed if the normal approximation to the binomial distribution does not apply due to small sample size or relative standard error (RSE) > 30%